Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical C*

血液和骨髓移植临床试验网络 (BMT CTN) - 核心临床 C*

• 批准号: 8678987
• 负责人: CLAUDIO ANASETTI
• 金额: $ 17.28万
• 依托单位: H. LEE MOFFITT CANCER CTR & RES INST
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-08 至 2017-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8678987
• 关键词: Acute Graft Versus Host Disease; Acute leukemia; Address; Allogenic; Antithymoglobulin; Area; Autologous; Behavior Therapy; Blood; Bone Marrow Transplantation; Cancer Center; Cancer Patient; Caring; Cells; Cessation of life; Clinical; Clinical Protocols; Clinical Research; Clinical Trials; Clinical Trials Design; Clinical Trials Network; Conceptions; Cyclophosphamide; Data; Data Analyses; Development; Diagnosis; Disease; Dose; Enrollment; Environment; Future; Goals; Haplotypes; Hematologic Neoplasms; Hematological Disease; Hematopoietic; Hematopoietic Stem Cell Transplantation; Hematopoietic stem cells; Human Herpesvirus 4; Immunobiology; Immunotherapy; Incidence; Individual; Institution; Instruction; Knowledge; Large-Cell Lymphomas; Literature; Lymphoproliferative Disorders; Malignant Neoplasms; Marrow; Measures; Medical; Multicenter Studies; Multicenter Trials; Multiple Myeloma; Patients; Phase; Prevention; Principal Investigator; Prophylactic treatment; Protocols documentation; Quality of life; Radiation therapy; Recurrence; Regimen; Relapse; Research; Research Infrastructure; Research Personnel; Resistance; Risk; Science; Secure; Severities; Siblings; Sirolimus; Source; Stem cells; Supportive care; Tacrolimus; Technology; Testing; Therapeutic; Toxic effect; Translational Research; Transplantation; Umbilical Cord Blood; base; cancer cell; chemotherapeutic agent; chronic graft versus host disease; conditioning; design; disability; disorder prevention; efficacy testing; evidence base; experience; graft vs host disease; illness length; improved; mortality; novel; novel strategies; peripheral blood; pilot trial; prevent; programs; randomized trial; reconstitution; rituximab; success

DESCRIPTION (provided by applicant): The goal of the BMT CTN is to conduct phase II and III multicenter trials to advance the hematopoietic stem cell transplantation (HSCT) technology and measure therapeutic advantages over non transplant therapies for hematopoietic disorders. The scientific environment of the Moffitt BMT Program will contribute to the success of the BMT CTN by providing fertile ground for the development of original concepts for multicenter trials, enrolling patients, and contributing to disseminate new knowledge in the field of HSCT. Specific Aim 1 (proposed concept): Test the efficacy of ATG for GVHD prophylaxis before unrelated donor HSCT in a phase III multicenter trial implemented by the BMT CTN. The addition of ATG to standard pharmacologic prophylaxis will provide more effective prevention of grade lll-IV acute GVHD following unrelated donor HSCT. ATG will also reduce chronic GVHD and improve patient quality of life. The efficacy of ATG for acute GVHD prophylaxis will not be fully realized until effective approaches are developed to reduce the incidence of Epstein-Barr Virus (EBV) reactivation and prevent post-transplant lymphoproliferative disorders (PTLD), that are the most serious complications of ATG therapy. In ATG- treated patients, we will test the hypothesis that rituximab prophylaxis can reduce the incidence of EBV reactivation compared to rituximab preemptive therapy. Specific Aim 2: Collaborate with the BMT CTN in the design and conduct of multicenter studies and the dissemination of the results. Although novel ideas start from individuals or teams of investigators commonly at a single center, significant advances in medical care occur through multicenter phase III randomized trials. The Moffitt Cancer Center has a fully established clinical and translational research program in HSCT with infrastructure to facilitate 400 HSCT per year. Our team brings expertise in GVHD immunobiology, myeloma therapy, behavioral therapy in cancer patients and evidence-based research. We perform now more than 350 HSCT including 130 allogeneic HSCT per year and pledge to make available BMT CTN trials available to patients receiving autologous and allogeneic HSCT in our institution. RELEVANCE (See instructions): The Blood and Marrow Transplantation Clinical Trial Network will advance transplantation technology by improving efficacy and decreasing toxicity of hematopoietic stem cell transplantation. The number of patients cured from blood disorders will increase. The Moffitt Cancer Center will contribute to the conception of multicenter clinical trials, patient enrollment, data analysis and knowledge dissemination.

描述（由申请人提供）：BMT CTN的目标是进行II期和III期多中心试验，以推进造血干细胞移植（HSCT）技术，并测量造血系统疾病相对于非移植疗法的治疗优势。Moffitt BMT项目的科学环境将有助于BMT CTN的成功，为多中心试验的原始概念的发展提供肥沃的土壤，招募患者，并有助于传播HSCT领域的新知识。具体目标1（提出的概念）：在BMT CTN实施的III期多中心试验中，检测ATG在无关供体HSCT前预防GVHD的疗效。将ATG添加到标准药物预防中将提供无关供体HSCT后III-IV级急性GVHD的更有效预防。ATG还将减少慢性GVHD并改善患者的生活质量。ATG预防急性GVHD的有效性将无法完全实现，直到开发出有效的方法来降低EB病毒（EBV）再活化的发生率和预防移植后淋巴组织增生性疾病（PTLD），这是ATG治疗最严重的并发症。在ATG治疗的患者中，我们将检验利妥昔单抗预防性治疗与利妥昔单抗预防性治疗相比可以降低EBV再激活发生率的假设。具体目标2：与BMT CTN合作设计和实施多中心研究并传播结果。虽然新的想法通常来自单个中心的个人或研究团队，但通过多中心III期随机试验，医疗保健取得了重大进展。Moffitt癌症中心在HSCT方面拥有完善的临床和转化研究计划，其基础设施每年可促进400例HSCT。我们的团队带来了GVHD免疫生物学，骨髓瘤治疗，癌症患者行为治疗和循证研究方面的专业知识。我们现在每年进行超过350例HSCT，包括130例同种异体HSCT，并承诺为在我们机构接受自体和同种异体HSCT的患者提供BMT CTN试验。相关性（参见说明）：血液和骨髓移植临床试验网络将通过提高造血干细胞移植的疗效和降低毒性来推进移植技术。治愈血液病的患者人数将增加。莫菲特癌症中心将为多中心临床试验、患者招募、数据分析和知识传播的概念做出贡献。